Loading stock data…
ASTELLAS PHARMA (4503.T)
TSE¥2,281-22.50 (-0.98%)
Market ClosedLast close Sep 8
Astellas Pharma Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Astellas Pharma Inc. in the Healthcare sector is trading at ¥2,280 with a market capitalization of $4.2T. Wall Street consensus targets ¥2,512 (14 analysts), implying a +10.2% move over the next 12 months. The stock is currently 16% below its 52-week high of ¥2,717, remaining 1.1% above its 200-day moving average. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +10.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Annual Financials
| Metric (JPY) · Annual | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
| Total Revenue | ¥1.52T↓ | ¥1.60T↓ | ¥1.91T↓ | ¥2.14T |
| Gross Profit | ¥1.23T↓ | ¥1.31T↓ | ¥1.56T↓ | ¥1.73T |
| Operating Income | ¥131.56B↑ | ¥18.95B↓ | ¥40.25B↓ | ¥380.06B |
| Net Income | ¥98.71B↑ | ¥17.05B↓ | ¥50.75B↓ | ¥291.54B |
Peer Comparison
JNJUNHPFE
Fundamentals
Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYL...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
¥4.22T
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
14.51
Beta
Defensive asset. Lower volatility than the S&P 500.
0.08
Div Yield
Strong income play. Yield provides a meaningful total return floor.
339.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
21.30%
Volume
Today's trading volume
3.78M
Recent News
Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President
President Donald Trump has secured new drug pricing agreements with nine pharmaceutical companies, with an aim to align the prices of drugs in the U.S. with international prices. The companies include Alcon Inc., Astellas Pharma, BeOne Medicines Ltd., BridgeBio, CSL,...
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
Trump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.
Mid-cap biotechs join Trump’s latest round of drug pricing deals
Focused on Medicaid, the new pacts now involve more than just large pharmaceutical companies, but still aren’t expected to meaningfully impact drugmaker profits.
Trump lines up MFN deals with nine mid-size pharmas on drug pricing push
These deals will require the companies to provide MFN prices to state Medicaid programmes nationally.
Trump's Pharma Pricing Deal Expands as Healthcare Stocks Keep Climbing
Trump expanded his drug pricing deal to 26 pharma firms as UBS says healthcare stocks still have room to climb.